Compare VNCE & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNCE | NSRX |
|---|---|---|
| Founded | 2002 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.4M | 53.5M |
| IPO Year | 2013 | N/A |
| Metric | VNCE | NSRX |
|---|---|---|
| Price | $3.05 | $5.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.50 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 51.8K | 2.3K |
| Earning Date | 03-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $293,452,000.00 | N/A |
| Revenue This Year | $4.16 | N/A |
| Revenue Next Year | $3.91 | N/A |
| P/E Ratio | $3.77 | ★ N/A |
| Revenue Growth | ★ 0.19 | N/A |
| 52 Week Low | $1.19 | $4.90 |
| 52 Week High | $4.65 | $9.99 |
| Indicator | VNCE | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 44.19 |
| Support Level | $2.41 | N/A |
| Resistance Level | $3.15 | $6.39 |
| Average True Range (ATR) | 0.17 | 0.74 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 88.24 | 30.57 |
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale, Vince Direct-to-consumer, and Rebecca Taylor and Parker segment. It operates its e-commerce business through its website. Majority of its revenue generated from Vince Wholesale segment.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.